SOURCE: Gene Express, Inc.

March 19, 2008 09:29 ET

Gene Express' David Lester, Ph.D. to Participate in Prominent Industry Conferences: the PharmaMedDevice Conference and Cambridge Healthtech Institute's 15th International Molecular Medicine Tri Conference

TOLEDO, OH--(Marketwire - March 19, 2008) - Gene Express, Inc. today announced that David S. Lester, Ph.D., Senior Vice President of Strategy and Corporate Development, will be participating in two upcoming industry conferences: the PharmaMedDevice Conference in Philadelphia, PA, March 26-28; and Cambridge Healthtech Institute's 15th International Molecular Medicine Tri Conference: Bridging Biology Chemistry and Business in San Francisco, CA on March 25-28.

At PharmaMedDevice, Dr. Lester will be participating in the panel discussion, "Personalized Medicine," along with Edward Abrahams, Executive Director of the Personalized Medicine Coalition, and Albert Di Rienzo, President and CEO of Blue Highway, LLC, on Wednesday, March 26 at 10:00am. He will be discussing the personalized medicine arena in relation to molecular diagnostics and the challenges of implementation in the U.S. healthcare system compared to global activities. Dr. Lester will highlight the opportunities, as well as the obstacles, facing this particular industry, and the best possible combinations of working with the various stakeholders, including Pharma, from a diagnostics company perspective.

To learn more about this event, please go to

At Cambridge Healthtech Institute's 15th International Molecular Medicine Tri Conference, Dr. Lester will be chairing an expert panel, "Putting Personalized Medicine into Clinical Practice," on Thursday, March 27 at 2:30pm. The panelists will include: Brian E. Ward, Ph.D., Senior Vice President, Genomic Health, Inc., Deborah Kilpatrick, Ph.D., Vice President of Market Development, CardioDx, Inc. and Robert A. Schueren, Ph.D., Head of Diagnostics, Genentech. The session will focus on the various perspectives of the company representatives presenting and addressing the challenges of introduction into clinical practice. The panel will tackle challenging questions such as: Who drives whom, i.e. is it Pharma or the Molecular Diagnostic industry? How will personalized medicine be delivered to the patient? Pricing and accessibility. Is personalized medicine relevant to new drugs being released on the market, or can it be applied to existing drugs? If existing drugs, how will the development be done? What is the impact of the FDA guidance on co-development of a drug and diagnostic?

To learn more about this event, please go to

David S. Lester received his Ph.D. in Biological Sciences from Northwestern University and has held positions at Harvard University Medical School, the Weizmann Institute of Science (Israel) and National Institute of Neurological Disorders and Stroke at the National Institute of Health. He is currently serving as Senior Vice President at Gene Express, Inc. in charge of Strategy and Corporate Development. Dr. Lester is also President of Innovative Technologies for Health and Wellness (ITHW, Inc.). He has held executive positions, and played pivotal roles at Pfizer, in the Global Clinical Technology and Human Health Technologies Groups, as well as at Pharmacia Corp., and at the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA). Dr. Lester's research interests have included the incorporation of innovative technologies into clinical trials for the use of biomarkers or surrogate endpoints. He has an extensive publication record including five edited volumes. Dr. Lester is active in numerous professional societies and has a strong record in public science policy activities.

About PharmaMedDevice

PharmaMedDevice is the first event to focus on the convergence of the medical device, pharmaceutical, and biologic industries as the future of combination products and drug delivery technology continue to evolve for 2008. This event is the first of its kind to address the needs of the combination products market and the exciting innovations taking place in drug delivery technology and healthcare today. This forum provides a dynamic platform for education, partnering, sourcing, and discovery of innovative, new combination products which offers cross-sector collaboration. It will provide industry professionals the opportunity to accelerate product innovation to establish a first to market advantage in a market that holds great promise for advancing patient care.

About Cambridge Healthtech Institute

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI's portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech's Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug and molecular diagnostic development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information